Terra Innovatum Global Recognized for Thought Leadership, Advancing Energy Equity, and Global Access to Clean Power Through its SOLO™ Micro-Modular Nuclear Reactor NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum” or the “Company”) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors today announced that it has been honored with a Special Mention for Sustainability at the 2025 United Nations Correspondents Association (UNCA) Awards Gala.Left to Right: Cesare Frepoli – Co-Founder & Chief Operating Officer at Terra Innovatum, Alessandro Petruzzi – Co-Founder & Chief Executive Officer at Terra Innovatum, Valeria Robecco – President at United Nations Correspondent Association (UNCA), Giordano Morichi – Founding Partner, Chief Business Officer &...

WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of the company on Tuesday, January 13 at 2:15 p.m. PT. A live webcast of the conference presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the event. About Repligen CorporationRepligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies...

VAL-D’OR, Quebec, Dec. 18, 2025 (GLOBE NEWSWIRE) — Cartier Resources Inc. (″Cartier″ or the ″Company″) (TSXV: ECR; FSE: 6CA) is pleased to announce the results of the Updated Mineral Resource Estimate (“MRE”) on its 100% owned flagship Cadillac Project, located in Val-d’Or (Abitibi, Quebec). The updated estimates include approximately 110,000 metres of drilling completed by Cartier from 2016 to 2024 as well as 420,000 metres drilling completed by previous mining companies. The MRE was independently prepared by PLR Resources Inc. and Evomine, specialists in mineral resource estimates and project evaluations, in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) and is dated December 17, 2025.  Strategic & Investment Significance Highlights of...

Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell’s Phase 3 clinical trial in metastatic breast cancer featured as “clinical trial to watch in 2026” BriaCell anticipates reporting top line data as early as H1-2026PHILADELPHIA and VANCOUVER, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce its Phase 3 Bria-IMT™ clinical trial in metastatic breast cancer has been prominently and independently featured in the Nature Medicine Year In Review’s publication, “Eleven clinical...

The combined Company will move forward as Decoy Therapeutics, Inc. and trade on the NASDAQ Stock Market under the ticker “DCOY” effective in early January 2026 Company to focus on advancing lead antiviral programs, expanding platform validation and achieving multiple data milestones Strategic 2026 roadmap designed to accelerate development, expand pipeline breadth, and drive long-term shareholder value HOUSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) — Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that in connection with its recent combination with Decoy Therapeutics Inc. (Decoy), the Company intends to change its corporate name to Decoy Therapeutics Inc. and its NASDAQ ticker symbol to DCOY. The planned name and ticker change mark a pivotal step in the Company’s transformation into a platform-driven biotechnology company...

Full-Year Revenues of $18.6 million and Net Loss of $2.2 million MISSISSAUGA, Ontario, Dec. 18, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its fiscal year and fourth quarter ended September 30, 2025 (“2025” and “Q4”) with revenues for those periods reflecting reduced antigen sales into China and cancellation of a client instrument and assay development program. Management DiscussionMicrobix added to both its capabilities and capacity across 2025, improving manufacturing processes, adding new products, and expanding its base of ongoing client relationships. However, setbacks relating to two clients (our distributor into China and a point-of-care assay-maker) overshadowed our broader progress – Resulting in reduced...

TORONTO, Dec. 18, 2025 (GLOBE NEWSWIRE) — McFarlane Lake Mining Limited (“McFarlane” or the “Company”) (CSE: MLM, OTC: MLMLF) is pleased to announce that exploration Drilling has commenced at its 100%-owned Juby Gold Project, located west of Gowganda, Ontario, within the southern part of the “Prolific Abitibi Greenstone Belt”. “Commencing drilling at Juby is an important milestone for McFarlane as we begin a meaningful exploration program on one of the largest gold systems in the southern Abitibi,” said Mark Trevisiol, President and CEO of McFarlane Lake Mining Limited. “With up to 13,000 metres planned across multiple zones, including priority targets at Golden Lake and Juby, this program is designed to expand known mineralization and test the project’s depth and strike potential. We believe Juby offers significant upside, and...

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Dec. 18, 2025 (GLOBE NEWSWIRE) — Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement for aggregate gross proceeds of C$177,500 (the “Private Placement”). The Private Placement consisted of the issuance and sale of 7,100,000 units of the Company (the “Units”) at a price of C$0.025 per Unit. Each Unit issued pursuant to the Private Placement consists of one Class A common share of the Company (a “Common Share”) and one-half of one Common Share purchase warrant of the Company (each whole...

Not for distribution to U.S. news wire services or dissemination in the United States WINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces that today it has completed its previously announced non-brokered private placement offering (the “Offering”) of common shares of the Company (“Shares”). At the closing of the Offering, Kane issued 14,000,000 Shares at a price of $0.05 per Share for gross proceeds of $700,000 to an insider of the Company. The net proceeds of the Offering will be used for working capital and general corporate purposes. All securities issued in connection with the Offering are subject to a hold period of four months and one day from the date of issuance. The closing of the Offering remains subject to the final approval of the TSX...

The financial calendar for Schouw & Co. for 2026 is as follows:5 March 2026 Release of Annual Report 202516 April 2026 Annual General Meeting21 April 2026 Expected payment of dividend for 20251 May 2026 Release of Q1 2026 interim report14 August 2026 Release of Q2 2026 interim report6 November 2026 Release of Q3 2026 interim reportResolution proposals from shareholders to be considered at the annual general meeting to be held on 16 April 2026 must be received by the company on or before Wednesday, 4 March 2026 Aktieselskabet Schouw & Co. Jørgen Dencker Wisborg                                                 Jens Bjerg SørensenChairman                                                                              President                                                                                           Questions...